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Introduction
Pain is the most common symptom for which patients seek medical attention [1] [2] [3] . The impact of chronic pain for the society is dramatic due to the high cost of medical treatment and loss in productivity. Opioids are a group of well-known pain relieving medicines, of which morphine (1) is the classical example (Figure 1 ), used to treat moderate to severe pain conditions such as cancerrelated pain, post-surgery pain, chronic low-back pain and pain associated to certain inflammatory diseases like osteoarthritis [4] [5] [6] . However, the adverse side effects and the development of tolerance and hyperalgesia, especially in long-term clinical use, hamper the widespread use of opioids for relieving pain. Opioids act by binding to and activating the opioid receptors (ORs) which belong to the superfamily of G protein-coupled receptors [7] [8] [9] . The effects of opioids such as morphine, either beneficial (analgesia) or adverse (sedation, respiratory depression, constipation, addiction), are mediated by the mu opioid receptor (MOR), by means of different downstream signalling and regulatory pathways. This receptor has two closely related receptor types (~70% sequence identity) named delta (DOR) and kappa (KOR) receptors. Since the isolation of morphine (1) in 1806 to the complete elucidation of its chemical structure, concluded in 1927 [10] , and the reports on detailed crystal structures of the ORs co-crystallized with their respective ligands in 2012 [7] [8] [9] , a plethora of semisynthetic derivatives of morphine (1) and related opioids has been made aiming at improving the analgesic potential while minimizing the side effects [11] [12] [13] [14] . Consequently, solid structure-activity relationships have been built and it is generally accepted that morphine-like activity and addiction liability is associated with the presence of the same stereochemistry as that of morphine (1), a relatively small alkyl group on the tertiary nitrogen at position 17 and a free aromatic hydroxy group at position 3 [11] [12] [13] [14] . Among the many chemical modifications of opioid compounds, oxidation at position 14 to give 14-hydroxy derivatives has successfully resulted in an increase in analgesic potency as in oxymorphone (2) and oxycodone (3) , and variation of the alkyl substituents at the nitrogen atom has led to the general conclusion that phenylethyl groups improve the analgesic activity whereas allyl or cyclopropylmethyl groups result in compounds such as naloxone (4) and naltrexone (5) that block the effect of opioids, through antagonistic behavior at the ORs (Figure 1 ).
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Despite the large number of semisynthetic derivatives of opioid compounds available up to now, which have mainly resulted from derivatization at positions 3, 6 and 17, chemical modification of the 7,8-double bond of opioids is seldom reported in the literature. This double bond has been mostly removed by reduction, in the preparation of some 7,8-dihydro derivatives of interest [15] [16] [17] [18] [19] [20] . Attempts to oxidize it using, for instance, peroxy acids yield side products derived from attack on the aromatic ring together with the double bond [21, 22] . The epoxidation of morphine proved unsuccessful and a 7β,8β-epoxide could only be obtained from 3-methoxymethylmorphinone, using hydrogen peroxide in aqueous methanol containing sodium hydroxide, revealing the relevance of the C6 substituent on the outcome of this oxidation [23, 24] . Oxidations with osmium tetroxide succeeded to give the respective diols [25] [26] [27] [28] . However, they were also highly dependent on the substituent present at C6, with more electron withdrawing substituents giving lower product yields. Overall, oxidations of opioids are challenging and almost exclusive to the production of 14-hydroxy derivatives from thebaine (6) and oripavine (7) , in route to the preparation of drugs such as naloxone (4) and naltrexone (5) (Figure 1 ) [19, 29] . Nonetheless, some oxidized products of opioids, namely 7,8-epoxides, have been suggested to bear less liability to dependence, with activity comparable to the parent compounds both in vitro and in vivo [23, 24] . We therefore envisioned that the establishment of a new protocol for the oxidation of the 7,8-double bond of opioids would be a useful means to produce versatile synthetic intermediates for opioid-related syntheses and to tackle the biological effects that resulted from the oxidation of this particular double bond.
Although the oxidation of codeine (8) (Figure 1 ) with aqueous permanganate has been reported [30] , to the best of our knowledge, there are no reports available on the use of solid-supported permanganate-based systems for the oxidation of opioids. These systems are advantageous as they involve heterogeneous reaction conditions, which are typically milder, allowing good to excellent product yields and recovery. In the particular case of potassium permanganate, they avoid handling of this reagent in the presence of water which results in unpractical and tedious work up procedures [31] . In addition, permanganate-mediated oxidations are usually recognized as eco-friendly because the co-product formed, manganese dioxide, can be recycled. Solid supports such as molecular sieves, graphite reagent, polystyrene, alumina, silica gel and copper sulfate pentahydrate have been previously used for permanganate-based oxidation of alcohols to carbonyl compounds, sulfides to sulfones, diols to lactones, and oximes to ketones [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] . The oxidation of olefins to diketones, α-hydroxy ketones and epoxides has been described with permanganate-supported on copper sulfate pentahydrate and iron(III) perchlorate hydrate [45, 46] . Herein we report the use of potassium permanganate supported on iron(II) sulfate heptahydrate for the oxidation of opioids as a convenient, one-step procedure for the preparation of previously unreported opioid 7β-hydroxy-8-ketones. Their structure and stereochemistry have been determined with the support of 1D and 2D nuclear magnetic resonance (NMR) and X-ray diffraction studies. Moreover, the affinity and activity of the new compounds towards ORs were determined by radioligand binding and receptor activation assays, and herein we provide novel insights into structure-activity relationships resulting from chemical modification at positions 7 and 8.
4
Previous research by the authors has shown that potassium permanganate (KMnO 4 ) supported on Fe(ClO 4 ) 3 ·nH 2 O successfully converts ∆ 5 -steroids to their corresponding steroidal α-hydroxy ketones, in high yields [46] . Therefore, we set out to investigate the use of this same system on the model opioid compound 11, which was prepared according to the synthesis depicted on Scheme 1. Table S1 , Entry 1 (Supporting info). However, the reaction mixture became very dense and quickly dried, and the reaction could not be effected even by addition of fresh amounts of solvent to the reaction medium. We next used permanganate-supported on CuSO 4 ·5H 2 O, according to the reaction conditions in Table S1 , Entry 2. This method has been previously reported for the oxidation of olefins to either α-hydroxy ketones, diketones or epoxides [45] . This time, the reaction proceeded in a relatively short time and we were able to isolate a single reaction product, corresponding to the 7β-hydroxy-8-ketone (12) (Scheme 1), however at a low yield of 52%. Therefore, we set out to screen the reaction with different metal salts including sulfates, nitrates and acetates in an attempt to improve the yield of desired product.
All metal sulfates tested were able to complete the reaction to give compound 12 as the single product with the exception of Ag 2 SO 4 , where mixtures of products, with the hydroxy ketone 12 as the major product, were obtained (Table S1 , Entries 3-6). High resolution mass spectrometry (HRMS) analysis of the crude reaction mixture revealed the presence of the 7,8-diol derivative and of unreacted starting material. Mixtures of products were also obtained with metal nitrates (Table  S1 , Entries 7-8) and with Cu(OAc) 2 ·H 2 O (Table S1 , Entry 9). In the presence of these salts, the isolation of product 12 was more difficult as t-BuOH was retained in significant amounts in the crude mixture. The best yield was obtained using FeSO 4 ·7H 2 O, with mild extension of the reaction time when compared to CuSO 4 ·5H 2 O (Table S1 , Entry 3). This is the first report on the use of FeSO 4 ·7H 2 O supported on KMnO 4 for the preparation of α-hydroxy ketones from olefins.
We next investigated which was the minimum amount of KMnO 4 that could be used in the presence of FeSO 4 ·7H 2 O to give compound 12, as this would most likely lower the amounts of MnO 2 formed at the end of the reaction and could help to improve the isolation procedure and final yield (Table  S1 , Entries 10-11). With amounts of oxidant lower than 0.5 g the reaction was slower and could not be completed. Nonetheless, under the conditions described in Table S1 , Entry 12, the reaction proceeded well with easier isolation of the final product, small compromise in time, and no compromise in yield. Two final runs were made in the absence of water or t-BuOH, under the best conditions given in Table S1 (Entry 12). Without t-BuOH, the reaction proceeded much slower and after 3 hours the expected compound 12 could be isolated, in 45% yield (Table S1 , Entry 13). However, without water (Table S1 , Entry 14), we observed decomposition of the starting material and no product was recovered, even after extension of the reaction time to 3 hours. These observations show that the presence of water is crucial for the success of the reaction and are consistent with a role of t-BuOH as a catalyst. 2D NMR experiments (Supporting info, Table S2 ) and single crystal X-ray diffraction measurements ( Figure 2 ) confirmed the structure and stereochemistry of compound 12, and provided important information for elucidating the reaction mechanism. On the newly formed hydroxy ketone 12, the stereochemistry of the chiral carbon 7 is (S) with the hydroxy group assuming an anti configuration in relation to the C6 acetoxy group, which suggests that the approximation of the permanganate ion to the double bond occurred on the less hindered face of the opioid 11 ( Figure 2 ). The oxidation of olefins with permanganate has been extensively studied and it is generally accepted that the reaction proceeds by formation of a cyclic manganate(V) intermediate, which is the limiting step ( Figure 2) 
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In reaction media where the basicity is low, disproportionation of this intermediate occurs leading to the formation of ketols. Systems comprising permanganate supported on metal salts such as the one in our work have been reported to proceed by Ω-phase catalysis where the water/t-BuOH mixture forms a third phase in the reaction medium, by surrounding the inorganic solids, where the reaction actually takes place [45] . We reason that this effect may account for an overall low basicity in our reaction medium leading the reaction to progress towards the formation of the hydroxy ketone 12.
To study the effect of the substituent present at C6 on the reaction outcome, we synthesized the opioid derivatives 15, 16 and 19 (Scheme 2). Compounds 15, 16 and 19 were then oxidized using the reaction conditions of Table S1 , Entry 12 (Scheme 3). The reaction was successful in all opioids and compounds 20, 21 and 22 were prepared with this method in 36, 34 and 15% yields, respectively, after chromatographic purification. The electron withdrawing effect of the oxygen atom is likely to account for the observed difference in the reactivity. This effect is more pronounced in the methoxy derivative 19 than on the siloxy derivatives 15 and 16. In compound 11, bearing an acetoxy group, this effect is the least pronounced due to electron delocalization between the two oxygen atoms. Of note, when the reaction was made using the 6-oxo derivative of compound 10, we observed degradation of the starting material and no products could be recovered. We next investigated the agonist or antagonist activities of compounds 17 and 23 using the 
Computational chemistry
The orthosteric binding sites of DOR, MOR, and KOR
The ORs belong to the rhodopsin-like GPCR family characterized by seven α-helical transmembrane segments. Crystallographic high-resolution structures have been solved for the three opioid receptor subtypes. The mouse DOR (mDOR) and hKOR have been co-crystallized with selective antagonists, respectively naltrindole (PDB code 4EJ4) and JDTic (PDB code 4DJH) [8, 9] . The mouse MOR has been crystallized with β-FNA (PDB code 4DKL), a covalently bound irreversible antagonist [7] , as well as with BU72 (PDB code 5C1M), a high efficacy agonist [50] . The three-dimensional structures allow a detailed atomistic view of the orthosteric binding site, formed by a crevice surrounded by the transmembrane segments 3-7, where the ligands are similarly bound ( Figures 4A and 4B ). The N-terminus is not part of the binding site in the antagonist-bound structures, but in the structure of the active MOR forms a lid on top of the binding cavity and interacts with the co-crystallized ligand [50] . The co-crystallized ligands occupy the same region of the binding pocket and accordingly, the amino acids at the binding site are highly conserved among the three OR subtypes ( 
In contrast to the message site, the amino acids located at the binding cavity's extracellular surface are more variable across the three OR subtypes, and consequently likely to play a significant role in selectivity. These amino acids have been named at the address site [51, 52] . Figure 4A and B, Supporting info, Figure S2 ). In comparison, at KOR the docking simulations suggest a small (~1.5-2.5 Å) shift around the ligand's positions 6 to 8, probably driven by steric clashes with tyrosine 7.35 (Supporting information, Figure   S2 ). The binding modes are overall in agreement with docking studies of the selective antagonists norbinaltorphimine and 5'-guanidinonaltrindole [8] . Docking simulations of the other four compounds, 11, 19, and 22 (mostly inactive) as well as 12 (mid-range µM activity at DOR) to the three subtypes led also to similar binding modes. An exception was found for compounds 11, 12 and 22 at KOR, where the compounds docked closer to TM2 than classical opioids, which may be due to the larger size of the acetoxy groups in positions 3 and 6 for compounds 11 and 12. 
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Structure-activity relationships
We assessed the binding affinities (competition binding assay) of six compounds for the MOR, DOR and KOR in comparison to morphine 1, with focus on four positions according to Table 3 . Positions 7 and 8 had either a double bond or were modified into a 7β-hydroxy-8-ketone moiety whereas positions 3 and 6 had hydroxy, methoxy, or acetoxy substituents. Position 17 had an Nmethyl carbamate in all cases. 
is exposed to the solvent ( Figure 5 ). With the exception of tyrosine 7.35 's phenolic group in KOR, which is at hydrogen bonding distance from the hydroxy group at position 7, the compound's 7 and 8 newly introduced positions do not seem to form polar interactions with the receptors. Solvent effects may thus be at the source of the inhibitory activity observed with introduction of 7β-hydroxy-8-ketone at DOR, however, these are very difficult to predict. In general, previous work in the literature does not provide a good framework to rationalize the effect of modifying positions 7 and 8. Reduction of the 7,8 double bond in morphine, leading to dihydromorphine, increases activity approximately by two fold at the DOR and MOR, but decreases it at the KOR by 8-fold [53] [54] [55] . When comparing dihydrocodeine to codeine (8), the activity is in contrast decreasing at DOR and KOR (respectively 6-and 2-fold) and increasing 8.5-fold at MOR [56] .
Considering the changes at positions 3 and 6, the hydroxy group is clearly preferred compared to methoxy or acetoxy. This can be seen by comparing the inhibitory activities of compounds 11, 12, 19, and 22 with the activities of compounds 17 and 23, i.e, at MOR, 3-11% vs 48-58%; at DOR 9-51% vs 59-63%; and to a lesser extent at KOR 0-10 % vs 21-27%. An interesting observation is that the conserved side chain nitrogen of lysine 5.39 is located near (3-4 Å) position 6 in most docked binding modes at MOR and DOR, where it would potentially form hydrogen bonds that support favoring of the hydroxy groups. Activities of compounds 17 and 23 at all three subtypes are unaffected by introduction of 7β-hydroxy-8-ketone, which may be due to this direct hydrogen bonding of position 6 with lysine 5.39 . For compounds 11, 12, 19 and 22, methoxy and acetoxy groups can be tolerated (or their activities even rescued) at the DOR upon introduction of a 7β-hydroxy-8-ketone, but this mechanism is not clarified by the docking study. Altogether the data presented is in line with the literature, where replacing both hydroxy groups with methoxy groups at positions 3 and 6 (e.g. morphine 1 and thebaine 6) leads to decreased binding (90-fold at MOR, 20-fold at DOR) [57] . If replacing the hydroxy with methoxy occurs solely at position 3 (morphine 1 and codeine 8), the decrease in activity is even more noticeable at MOR and KOR (700-fold and 300-fold, respectively), however lower at DOR (3-fold) [58] . In contrast, modifying position 6 (morphine 1 and heterocodeine) leads to increased binding by 3.6-fold at the MOR, 5-fold at the DOR, but is unchanged at KOR [17] .
Concerning position 17, compound 1 is easily compared to compound 17, which are otherwise identical. At MOR, in 17 the loss of the positive charge and the associated loss of salt bridge with aspartate 3.32 led to a 250-fold increase in K i and significant loss of radioligand binding inhibition, from 85% at 10 µM for 1 (K i ~0.004 µM, [54] ) to 58 % for 17 (K i ~1 µM) (Supporting info, Table  S3 ). At KOR K i has not been determined, but the fold difference is probably even higher than at MOR, since morphine (1) displays 80% inhibition of radioligand binding at 10 µM (K i 0.028 µM) while compound 17 displays only 27% inhibition. At DOR there is surprisingly only limited loss of activity associated with the loss of the positive charge, i.e., only 6-fold: morphine has 63% inhibition (K i ~0.34 µM) at DOR, while 17 has 59% inhibition (K i ~2 µM). In addition to charge, in most binding modes, the carbamate fits well into a hydrophobic pocket lined by amino acids tryptophan 6.48 , glycine 7.42 , tyrosine 7.43 and aspartic acid 3.32 . Altogether N-alkylation should thus be associated with a large gain in activity. Nonetheless, we were unable to produce N-alkylated compounds within the time frame of the project that supported this work, and especially regulations about opioid substances hindered further work in this direction. Of note, charge is not a requirement M A N U S C R I P T
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for high activity at ORs. Nanomolar ligands without protonable nitrogen atoms are active at the KOR such as salvinorin A, which partially occupies the orthosteric binding pocket as demonstrated by covalent salvinorin A analogs binding at the KOR [8] .
Altogether, concerning determinants of selectivity, the presence of tyrosine 7.35 in the vicinity of positions 7 and 8 at KOR may be linked to the lower activity at that receptor in comparison to MOR and DOR (respectively tryptophan /leucine 7.35 ). Docking simulations suggest that selectivity could be driven through a small shift in ligand binding mode at KOR relative to the other subtypes (see above) that would prevent interactions between the hydroxyl group in position 6 and lysine 5.39 .
Glutamate 6.58 in KOR (lysine/tryptophan 6.58 ) is ~10 Å further away but may also play a role.
Conclusion
7β-Hydroxy-8-ketone opioids can be prepared in one-step and easily isolated, under heterogeneous conditions, using potassium permanganate supported on metal salts. Our study reveals that the most suitable metal salt for this transformation is iron(II) sulfate heptahydrate and that a number of opioids, bearing different functional groups, can be converted into the expected hydroxy ketones.
Better yields are obtained with opioids bearing electron-donating groups at position 6. Mechanistically, the reaction is thought to proceed via formation of a cyclic manganate(V) intermediate that undergoes disproportionation to give the hydroxy ketone. The compounds act as antagonists at MOR and DOR. Overall, our work provides valuable tools for those working in the field of opioids chemistry, as the 7β-hydroxy-8-ketones can be regarded as a good starting point for further syntheses. Herein we have shown that chemical modification at positions 7 and 8 of opioids can lead to increased selectivity at the DOR.
Experimental
Chemistry. The reagents were obtained from Sigma Aldrich Co., VWR International Oy, or Merck Reagenzien. For thin layer chromatography (TLC) Silica gel 60 F254 was used. Flash column chromatography (FCC) was made with a Biotage High-Performance Flash Chromatography Sp4-system (Uppsala, Sweden) using a 0.1-mm path length flow cell UV detector/recorder module (fixed wavelength: 254 nm), and 10 g, 25 g or 50 g SNAP cartridges (10-50 mL/min flow rate). The melting points were measured with Stuart SMP40 automated melting point apparatus and are uncorrected. IR spectra were obtained using a Vertex 70 (Bruker Optics Inc., MA, USA) FTIR instrument. The FTIR measurements were made with a horizontal attenuated total reflectance (ATR) accessory (MIRacle, Pike Technology, Inc, WI, USA). The transmittance spectra were recorded at a 4 cm -1 resolution between 4000 and 600 cm -1 using the OPUS 5.5 software (Bruker Optics Inc., MA, USA). NMR spectra were obtained using a Varian Mercury Plus 300 spectrometer or Bruker Ascend 400 spectrometer, in CDCl 3 or CD 3 OD, with tetramethylsilane (TMS) as the internal standard. The chemical shifts were reported in parts per million (ppm) and on the δ scale from tetramethylsilane (TMS) as an internal standard. The coupling constants J are quoted in Hertz (Hz). If rotamers are observed in the 13 C spectrum, the minor rotamer peaks are labelled with *. General procedure for oxidations (Table S1) The respective starting material (0.5 mmol) was dissolved in dichloromethane. The metal salt and KMnO 4 were ground to fine powder and added to the stirred solution, followed by water and tBuOH. The mixture was stirred at room temperature and monitored with TLC. When the reaction was complete, the reaction mixture was diluted with diethyl ether (10 mL) and stirred for 3 minutes. The mixture was filtered through a Celite pad and the pad was washed several times with diethyl ether (150 mL in total). The filtrate was washed with water (30 mL), dried with anhydrous Na 2 SO 4 , filtered and concentrated to dryness.
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N-Methyl 3,6-di-acetyl-4,5-epoxy-7-hydroxy-8-oxo-(5α,6α,7β)-morphinan carbamate (12).
Compound 12 was prepared according to the general procedure described above under the reaction conditions described on (20) . Compound 20 was prepared according to the general procedure described above under the reaction conditions described on Table S1 , Entry 12. 
N-methyl 3,6-bis[[(1,1-dimethylethyl)diphenylsilyl]oxy]-4,5-epoxy-7-hydroxy-8-oxo-(5α,6α,7β)-morphinan carbamate
N-Methyl 4,5-epoxy-7-hydroxy-3,6-dimethoxy-8-oxo-(5α,6α,7β)-morphinan carbamate (22).
Compound 22 was prepared according to the general procedure described above under the reaction conditions described on N-Methyl 4,5-epoxy-3,6,7-trihydroxy-8-oxo-(5α,6α,7β)-morphinan carbamate (23) . Compound 12 (297 mg, 0.667 mmol) was dissolved in a mixture of methanol: chloroform (4:1, 10 mL). A 0.1 M aqueous solution of NaOH (4.5 mL) was added and the resulting white suspension was stirred at room temperature for 2.5 h. The organic solvents were evaporated and the pH of the residue was adjusted to 6 with a 1 M aqueous solution of HCl. The aqueous phase was extracted with a mixture of chloroform: isopropanol 4:1 (3 × 20 mL) and the combined organic phases were washed with brine (18 mL), dried with anhydrous Na 2 SO 4 , filtered and concentrated in vacuo to give a light brown solid. The crude product was purified with automated column chromatography by eluting M A N U S C R I P T 7,8-Didehydro-4,5-epoxy-6-hydroxy-17-methyl-(5α,6α)-morphinan-3-carboxylate (9) . Morphine (1, 0.500 g; 1.75 mmol) was added to a stirred mixture of NaHCO 3 (8.00 g; 95.3 mmol) and water (50 mL), at room temperature. Acetic anhydride (4 × 0.83 mL; 8.76 mmol) was added slowly in 4 portions in 10-minute intervals and after the last addition the stirring was continued for 15 min. The reaction mixture was extracted with dichloromethane (3 × 60 mL), washed with brine (40 mL) and dried with anhydrous Na 2 SO 4 , filtered and concentrated in vacuo to give 9 as light brown foam (643 mg, 99%), which was used without further purification. 
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N-Methyl 3-acetyl-7,8-didehydro-4,5-epoxy-6-hydroxy-(5α,6α)-morphinan carbamate (10).
Compound 9 (638 mg; 1.95 mmol) was dissolved in dry chloroform (60 mL) under argon. NaHCO 3 (2.46 g; 29.2 mmol) and methyl chloroformate (2.56 mL; 33.1 mmol) were added and the mixture was refluxed at 62 °C for 3 hours. The reaction mixture was cooled to room temperature, diluted with dichloromethane (60 mL) and washed with water (40 mL). The aqueous phase was extracted with dichloromethane (3 × 35 mL). The organic phases were combined, washed with brine (40 mL), dried with anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The crude product was purified by automated column chromatography by eluting with a gradient of n-hexane and ethyl acetate (0 → 100% EtOAc) to give compound 10 as a white solid (574 mg, 79% 
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N-Methyl 3,6-diacetyl-7,8-didehydro-4,5-epoxy(5α,6α)-morphinan carbamate (11) . Compound 10 (0.100 g, 0.269 mmol) was dissolved in pyridine (0.62 mL) and acetic anhydride (0.11 mL, 1.13 mmol) was slowly added. The reaction mixture was stirred at 90 °C for 2.5 h, after which the solvent was co-evaporated with toluene. The residue was dissolved in dichloromethane (30 mL) and washed with aqueous saturated NaHCO 3 solution (10 mL). The aqueous phase was extracted with dichloromethane (3 × 10 mL), the organic phases were combined and washed with brine (8 mL), dried with anhydrous Na 2 SO 4 , filtered and concentrated in vacuo to give brown oil. The crude product was purified with automated column chromatography by eluting with an n-hexane/ethyl acetate gradient (3:2 to 1:1) to give 11 as a white solid (88.0 mg, 79% (14) . Morphine 1 (0.600 g; 2.10 mmol) and imidazole (726 mg; 10.7 mmol) were dissolved in dry dimethylformamide (3.6 mL) under argon. t-Butyldimethylsilyl chloride (1.20 g; 7.96 mmol) was added and the reaction mixture was heated at 90 °C for 4 hours. The reaction mixture was diluted with dichloromethane (40 mL), washed with water (2 × 20 mL), dried with anhydrous Na 2 SO 4 and concentrated in vacuo. The crude product was purified using automated column chromatography by eluting with a chloroform → methanol gradient (0 → 4%) to give compound 14 as light brown solid (677 mg, 63% (15) . Compound 13 (0.760 g; 0.997 mmol) was dissolved in dry chloroform (32 mL) under argon. NaHCO 3 (1257 mg; 15.0 mmol) and methyl chloroformate (1.31 mL; 17.0 mmol) were added and the mixture was refluxed at 62 °C for 2 h 20 min. The reaction mixture was diluted with dichloromethane (20 mL) and washed with water (35 mL). The aqueous phase was extracted with dichloromethane (2 × 20 mL). The organic phases were combined, washed with brine (30 mL), dried with anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The crude product was purified by automated column chromatography by eluting with n-heptane/ethyl acetate (5:1) to give compound 15 as a colorless solid (659 mg, 82% (17) .
Compound 11 (127 mg, 0.307 mmol) was dissolved in a mixture of methanol: chloroform (7:2, 4.5 mL). A 0.1 M aqueous solution of NaOH (2.2 mL) was added to the solution and the resulting white suspension was stirred at room temperature for 30 min. The organic solvents were evaporated, water (5 mL) was added to the residue, and the pH of the aqueous phase was adjusted to 5 with a 1 M A N U S C R I P T A C C E P T E D Grid generated was centered on the centroid of the co-crystallized ligands that indicates well the center of the orthosteric binding pocket. For DOR and MOR, the ligand docking method was based on a rigid protein. For KOR the rigid protein did not lead to reasonable solutions (KOR ligands located very high in the binding pocket) but reasonable solutions were delivered by the induced-fit protocol; induced fit dockings at the KOR are therefore presented in this manuscript. Prior to docking ligand preparation was performed with standard parameters with LigPrep (pH 7.0 ± 2). The poses were selected based on the best docking score, but alternative poses were also considered. Water molecules were not considered during the docking runs. PyMOL was used for visualizing the results [61] .
Biology
Materials -DAMGO, naltrindole, naloxone and GDP were obtained from Sigma. GTP was from Thermo Scientific. [ 3 H]Diprenorphine (specific activity, 37 Ci/mmol) and [ 35 S]GTPgS (specific activity, 1250 Ci/mmol) were obtained from PerkinElmer Life Sciences, SNC80 and U50488 from Tocris (Bio-Techne, Lille, France), and morphine from Francopia (Gentilly, France). Stably transfected cells expressing human (h) MOR (HEK), DOR (HEK) and KOR (CHO) were obtained and cultured as described [48, 49] . K D , K i and B max values were determined using the Prism software (GraphPad, San Diego, CA).
Cell viability -The toxicity of the compounds 12, 17, 22 and 23 was evaluated on HEK-293 cells by cell viability assay. The cells 9000 cells/well) were incubated in the presence of the compounds (0.1-100 µM) for 24 hours. The growth medium was changed to Opti-MEM prior to the addition of the compounds. CellTiterGlo reagent was used for cell lysis and determination of the ATP levels of the lysate from luminescence. The results were analyzed using Prism software (GraphPad, San Diego, CA). No effect on cell viability was seen at concentrations lower than 100 µM (Supporting info, Figure S3 ), showing that these compounds do not have any inherent properties that would interfere strongly with the basic functions of living cells.
Cell Membrane Preparations -Membranes from transfected cells were obtained as previously described [48, 49] . Briefly, cells were washed with phosphate-buffered saline (PBS, pH 7.4), scrapped off the plates with PBS, pelleted by centrifugation at 1500 rpm for 10 min at room temperature and frozen at -80 °C. All the following steps were performed at 4 °C. The pellet was M A N U S C R I P T
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thawed and suspended in 30 mL of cold 50 mM Tris-HCl, pH 7.4, 1 mM EDTA and 0.1 mM phenylmethylsulfonyl fluoride (added extemporaneously). The cell lysate was Douncehomogenized (30 ×) and centrifuged at 2500 rpm for 10 min. The pellet was resuspended in the buffer (15 mL), Dounce-homogenized (30 ×), and centrifuged again at 2500 rpm 10 min. Both supernatants were combined and ultracentrifuged at 40,000 rpm for 25 min. The pellet was resuspended in 5 mL of 50 mM Tris-HCl, pH 7.4, 1 mM EDTA and 0.32 M sucrose and Douncehomogenized (10 ×). The membrane preparations were aliquoted and stored at -80 °C. Protein concentration was determined using the Bradford assay.
Receptor Binding Assay -For saturation experiments, a range of 
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